Compare Micron Technology, Inc. (MU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Micron Technology, Inc. trades at $888 (market cap $980.90B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Micron Technology, Inc. is far larger — about 7.3× Vertex Pharmaceuticals Incorporated's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MU | VRTX | |
|---|---|---|
Market Cap | $980.90B | $134.25B |
Sector | Technology | Health |
52-Week High | $1.21K | $529.65 |
52-Week Low | $115.79 | $376.62 |
Enterprise Value | $961.25B | $128.37B |
Dividend Yield | 0.06% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
